Article

Isolated Gastric Metastases of Pancreatic Ductal Adenocarcinoma following Radical Resection—Impact of Endosonography-Guided Fine Needle Aspiration Tract Seeding

Martin Loveˇ cek 1, Pavel Skalický 1, Ondˇ rej Urban 2, Jana Tesaˇ ríková 1, Martin Kliment 3, Róbert Psár 4, Hana Švébišová 5, Kateˇ rina Urban 6, Beatrice Mohelniková-Duchoňová 6,7, Dušan Klos 1 and Martin Stašek 1,∗

1 Department of Surgery I, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic; martin.lovecek@fnol.cz (M.L.); pavel.skalkicky@fnol.cz (P.S.); jana.tesarikova@fnol.cz (J.T.); dusan.klos@fnol.cz (D.K.)
2 Department of Internal Medicine II—Gastroenterology and Geriatrics, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic; ondrej.urban@fnol.cz
3 Helios Kliniken Schwerin, Klinik für Gastroenterologie und Infektologie, Wismarsche Strasse 393-397, 19055 Schwerin, Germany; martin_kliment@hotmail.com
4 Department of Radiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 976/3, 77900 Olomouc, Czech Republic; psar.robert@gmail.com
5 Department of Oncology, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic; hana.svebisova@fnol.cz
6 Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic; katerina.kolarova@upol.cz (K.U.); beatricemohelnikova.duchonova@fnol.cz (B.M.-D.)
7 Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská 976/3, 77900 Olomouc, Czech Republic
∗ Correspondence: martin.stasek@fnol.cz; Tel.: +42-058-844-2962

Abstract: Background: Endosonography-guided fine needle aspiration biopsy (EUS-FNA)-associated metachronous gastric seeding metastases (GSM) of pancreatic ductal adenocarcinoma (PDAC) represent a serious condition with insufficient evidence. Methods: Retrospective analysis of PDAC resections with a curative-intent, proven pathological diagnosis of PDAC, preoperative EUS-FNA and post-resection follow-up of at least 60 months. The systematic literature search of published data was used for the GSM growth evaluation using Pearson correlation and the linear regression analyses. Results: The inclusion criteria met 59/134 cases, 16 (27%) had retained needle tract (15 following distal pancreatectomy, 1 following pylorus-sparing head resection). In total, 3/16 cases (19%) developed identical solitary GSM (10–26th month following primary surgery) and were radically resected. A total of 30 published cases of PDAC GSM following EUS-FNA were identified. Lesion was resected in 20 distal pancreatectomy cases with complete information in 14 cases. A correlation between the metastasis size and time (r = 0.612) was proven. The regression coefficient b = 0.72 expresses the growth of 0.72 mm per month. Conclusions: The GSM represent a preventable and curable condition. A remarkably high number of GSM following EUS-FNA was identified, leading to follow-up recommendation of EUS-FNA sampled patients. Multimodal management (gastric resection, adjuvant chemotherapy) may prolong survival.

Keywords: pancreatic adenocarcinoma; endoscopic ultrasound; fine-needle aspiration biopsy; needle tract seeding; gastric metastasis

1. Introduction

Tissue confirmation of pancreatic ductal adenocarcinoma (PDAC) can be carried out using minimally invasive methods, such as percutaneous abdominal sampling (PAS) or endoscopically guided fine needle aspiration (EUS-FNA) [1]. EUS-FNA is considered
accurate (sensitivity 85–92%; specificity 96–99%) and safe diagnostic method for verification of malignant cells in pancreatic solid lesions [1–6]. The reported complication rate of EUS-FNA is low (0.98–1.03%) [7,8]. The data on long-term complications including tumor seeding are rare and not congruent [1,9]. Regardless of the extremely rare occurrence of EUS-FNA-associated seeding metastases, they belong to late serious EUS-FNA-associated complications that may decrease the individual survival [7]. Thus far, only one multicentric Japanese study with six cases [10] and twenty-four case reports referring to needle tract seeding metastases of PDAC following EUS-guided sampling have been reported worldwide until 2022 [1,3,7,8,11–30]. Moreover, only 20 cases of those documented seeding PDAC metastases have been solved surgically with resection so far [3,7,8,10,13,19,21–30].

The aim was to analyze a cohort of PDAC patients who underwent curative-intent surgery with previous EUS-FNA verification and summarize all the data regarding EUS-FNA-associated seeding PDAC metastases. According to the guidelines (ESMO—European Society for Medical Oncology; S3—German guidelines), tissue confirmation is considered unnecessary for resectable PDAC. Clinical practice is still different and most resectable PDAC are still referred to surgery following EUS-FNA.

2. Materials and Methods

Retrospective analysis of a prospectively maintained single-center database of PDAC patients operated on with curative intent (2010–2014), who underwent EUS-FNA before the surgery. All the data in the database had been collected prospectively, including tumor type, tumor location, stage, type of surgical procedure, oncological treatment, disease-free survival (DFS), recurrence location, additional treatment and overall survival (OS). The inclusion criteria of the study were as follows: (1) a curative-intent surgical treatment; (2) histopathological diagnosis of PDAC; (3) a preoperative EUS-FNA diagnostic procedure; and (4) post-resection follow-up comprising biochemical tumor markers monitoring (CA 19-9, CEA, CA 125) every 3 months, and imaging-computed tomography (CT) or positron emission tomography/computed tomography (PET/CT) scans performed every 6–12 months or in the case of CA 19-9 elevation. The exclusion criterion was extragastric recurrence (liver, peritoneum, lymph nodes, locoregional, lung, or multiple). All tissue samples (primary tumor, EUS-FNA samples and resected stomach wall with metastases) were verified by two independent pathologists. Seeding PDAC metastases (gastric wall recurrence) of pancreatic cancer were defined as histologically proven recurrent pancreatic cancer located in the area corresponding to the prior EUS-FNA channel, usually in a gastric wall. DFS was measured as the period between the date of surgery and the diagnosis of cancer recurrence. The OS was measured as the period between the date of surgery and the date of death.

Curative-intent surgery for body and tail tumor localization was distal pancreatectomy with splenectomy and standard lymphadenectomy according to International Study Group for Pancreatic Surgery (ISGPS) and the pylorus-preserving hemipancreatoduodenectomy (Traverso modification) with standard lymphadenectomy for periampullary or head localization. All EUS-FNA with 22-gauge needles were carried out by three experienced endosonographers with 2–4 needle passes.

The Pearson correlation analysis and linear regression analysis of data from cases presented thus far and of our patients were used to evaluate the growth rate and time. The IBM SPSS Statistics version 22 (IBM, Armon, New York, USA) was used to analyze the data. The study has been approved by the Institutional Ethical Committee, corresponding ethical approval code 159/16.

3. Results

The analysis identified 59 (44%) PDAC cases with preoperatively performed EUS-FNA from the database of 134 patients (Table 1). The group consisted of 44 following pancreas head resections—43 with a resected area of previous EUS-FNA during the curative-intent surgery and 15 patients following distal pancreatectomy (27%), in whom the retained see-
dle tract area remained in the gastric wall (1 in a group of head location and 15 in a group of body/tail location). Fourteen of them (14/16) survived more than 1 year without radiologically proven recurrence. In three (19%) patients from this group (No = 16), an unusual location of metachronous oligometastases (gastric wall without serosal involvement) was found (Figures 1−3). From the histopathological point of view, primary pancreatic tumor and secondary resected metastases in the stomach/pylorus have identical histopathological findings (Table 1).

Figure 1. (a) Histopathological specimen of pancreatic tissue with well-differentiated ductal adenocarcinoma of pancreatic head. (b) Pyloric tissue with well-differentiated ductal adenocarcinoma of pancreatic origin, identical morphology with primary pancreatic tumor. No signs of a primary gastric adenocarcinoma. Hematoxylin/Eosin.

Figure 2. (a) Histopathological specimen of pancreatic tail tissue with well- and moderate-differentiated ductal adenocarcinoma. (b) Posterior stomach wall tissue with well- and moderate-differentiated ductal adenocarcinoma. Identical morphology with a primary pancreatic tumor. No signs of primary gastric adenocarcinoma. Hematoxylin/Eosin.
Table 1. Flow chart of PDAC patients included in the study.

| PDAC Patients Radically Resected with Curative Intent | 134 |
|------------------------------------------------------|-----|
| Head                                                 | 107 |
| Excluded (no EUS-FNA)                                | 63  |
| Preoperative EUS-FNA                                 | 44  |
| Excluded                                             | 43  |
| Resected                                             | 1   |
| 1-year disease-free interval                         | 1   |
| **Body and Tail**                                    | 27  |
| Excluded (no EUS-FNA)                                | 12  |
| Preoperative EUS-FNA                                 | 15  |
| Excluded                                             | 0   |
| Resected                                             | 15  |
| 1-year disease-free interval                         | 13  |

(a) (b) 

Figure 3. (a) Histopathological specimen of pancreatic tail tissue with well- and moderate-differentiated ductal adenocarcinoma. (b) Posterior stomach wall tissue with well- and moderate-differentiated ductal adenocarcinoma. Identical morphology with primary pancreatic tumor, no signs of primary stomach adenocarcinoma. Hematoxylin/Eosin.

The location of the primary tumor in the body/tail of the pancreas and primary procedure in two patients were distal pancreatectomies with splenectomy and lymphadenectomy. The third one was a unique case of recurrence following pylorus-preserving hemipancreateoduodenectomy, since no such case has been published previously. Radical resections of seeding metastases with uneventful recovery were completed in all three cases. The patients’ demographics, clinical characteristics and their treatment are summarized in Table 2. None of them had an early recurrence of the disease (during the first 6 months after the seeding metastasis resection).

Literary research and subsequent evaluation pointed out 30 published cases of PDAC GSM. Complete information for the progression analysis of seeded tumors was gained in 14 cases, as shown in Figure 4. All cases of seeding/needle tract metastases are illustrated in Table 3. There was a moderate positive correlation between size and time (r = 0.612). The regression coefficient b = 0.72 is significantly non-zero (p = 0.020) and expresses an increase by 0.72 mm in one month.
Table 2. Clinical characteristics of patients with proven gastric seeding of PDAC.

|            | Case 1                  | Case 2                  | Case 3                  |
|------------|-------------------------|-------------------------|-------------------------|
| Gender     | M                       | F                       | F                       |
| Age        | 65                      | 71                      | 75                      |
| Presentation | Abdominal pain        | Abdominal pain, weight loss | Jaundice               |
| EUS-FNA complication | Haemoperitoneum    | 0                        | 0                        |
| Presentation—Surgery delay | 23 M (patient refusal) | 1.5 M                  | 1 M                     |
| Surgery    | Distal pancreatectomy, splenectomy | Distal pancreatectomy, splenectomy | Hemipancreatoduodenectomy s. Traverso |
| TNM stage, G | pT3N1 M0, G1,R0     | pT1 N0 M0, G2,R0       | pT3 N0 M0, G3,R0       |
| Oncological therapy | CHT, RT          | CHT                     | CHT                     |
| Chemotherapy | 5-FU              | Gemcitabine 4 cycles   | 0                       |
| Radiotherapy | 50.4 Gy            | 0                       | 0                       |
| Gastric lesion presentation | Asymptomatic (PET/CT, EUS) | Asymptomatic (PET/CT, EUS) | Vomiting, weight loss, pylorus obstruction |
| Postsurgical delay | 10 M              | 26 M                    | 18 M                    |
| Serum Ca-19-9 level | 1344 kIU/l           | 796.5 kIU/l           | 0.6 kIU/l              |
| Diameter   | 30 mm                  | 25 mm                   | 20 mm                   |
| Oncological therapy | Gemcitabine 5 cycles | 0                       | 0                       |
| Surgery    | Distal stomach resection, lymphadenectomy | Distal stomach resection, lymphadenectomy | Pyloric resection, lymphadenectomy |
| Lymphadenectomy type/positivity | D1 (0 positive) | D1 (3/11 positive) | Peripyloric (2/4 positive) |
| Single/multiple; serosal involvement | Multiple; no serosal involvement | Single; no serosal involvement | Single; no serosal involvement |
| Subsequent therapy | DeGramont regimen CHT 7 cycles | Gemcitabine 5 cycles | 0                       |
| Total survival | 56 M               | 82 M (alive)           | 28 M                    |
| Survival following gastric resection | 10 M               | 54 M (alive)           | 10 M (no signs of recurrence) |

Figure 4. The correlation of time from the EUS-guided FNA and the size of gastric seeding metastasis.
Table 3. Reported cases of needle tract seeding metastasis after EUS-FNA for pancreatic adenocarcinoma.

| Author            | Year | Age | Sex | Location   | Tumor mm | Passes | Needle G | Treatment | Stage | Recur. M | Size mm | Treatment |
|-------------------|------|-----|-----|------------|----------|--------|----------|-----------|-------|----------|---------|-----------|
| Hirooka           | 2003 | 57  | M   | Body       | 20       | 3      | 22       | DiPE      | T1N0M0| 1        | Micro   | PaGE      |
| Paquin            | 2005 | 65  | M   | Tail       | 22       | 5      | 22       | DiPE      | T1N0M0| 21       | 50      | CHT       |
| Ahmed             | 2011 | 79  | M   | Body       | NR       | NR     | NR       | CePE      | T2N0M0| 39       | 45      | TGE       |
| Chong             | 2011 | 55  | F   | Tail       | 27       | 3      | 22       | DiPE      | T2N0M0| 26       | 40      | NR        |
| Katanuma          | 2012 | 68  | M   | Body       | 20       | 4      | 22       | DiPE      | T2N0M0| 22       | NR      | NR        |
| Anderson          | 2013 | 51  | M   | Head       | 50       | NR     | NR       | CHT       | NR    | NR       | 10      | NR        |
| Nga wormungphong  | 2013 | 66  | M   | Body/Tail  | NR       | 3      | 22,19    | STPE      | NR    | 27       | NR      | NR        |
| Nga wormungphong  | 2013 | 77  | F   | Tail       | 40       | 3      | 19       | DiPE, PaGE| NR    | 26       | NR      | NR        |
| Sakurada          | 2015 | 87  | F   | Body       | 25       | NR     | 22       | DiPE      | T2N0M0| 8        | 12      | PaGE      |
| Minaga            | 2015 | 64  | M   | Body       | 20       | 3      | 22       | DiPE      | T3N0M0| 28       | 32      | sTGE      |
| Tomonari          | 2015 | 78  | M   | Body       | 20       | 2      | 22       | DiPE      | T3N0M0| 27       | NR      | PaGE      |
| Kita              | 2016 | 68  | F   | Body       | NR       | 2      | 22       | RT        | NR    | 4        | NR      | PaGE      |
| Yamabe            | 2016 | 75  | M   | NR         | 30       | NR     | 25       | CHT       | NR    | 3        | 24      | CHT       |
| Minaga            | 2016 | 72  | M   | Body       | 10       | NR     | NR       | DiPE      | T1N0M0| 23       | 28      | PaGE      |
| Iida              | 2016 | 78  | F   | NR         | 3        | 22      | 2        | DiPE      | T3N0M0| 6        | 18      | PaGE      |
| Yamanuchi         | 2018 | 50  | M   | Tail       | 38       | 2      | 22       | DiPE      | T4N1M0| 24       | 20      | PaGE      |
| Sakamoto          | 2018 | 50  | M   | Body       | 35       | 3      | 21       | DiPE, PaGE| NR    | 8        | NR      | PaGE      |
| Matsumoto         | 2018 | 50  | M   | Body       | 35       | 3      | 21       | DiPE, PaGE| NR    | 8        | NR      | PaGE      |
| Matsui            | 2019 | 68  | F   | Body       | 15       | 4      | 19–22    | DiPE, PaGE| T1N1M0| 1        | micro    | PaGE      |
| Matsui            | 2019 | 70  | M   | Body       | 34       | 1      | 23       | DiPE, PaGE| T3N0M1| 4        | micro    | PaGE      |
| Kawabata          | 2019 | 78  | F   | Body       | 11       | NR     | 22       | DiPE      | T1N0M0| 36       | 25      | PaGE      |
| Sato              | 2020 | 83  | F   | Body       | 25       | 2      | 22       | DiPE      | T2N1bM0| 22       | 23      | PaGE      |
| Rothermel         | 2020 | 61  | M   | Body       | 37       | 3      | 25       | DiPE      | T3N0M0| 42       | 25      | WGE       |
| Okamoto           | 2020 | 72  | F   | Tail       | 42       | 5      | 22       | DiPE + PaGE| T3N1M0| -        | micro    | CHT (Folfirinox) |
| Yane              | 2020 | 66  | F   | Tail       | NR       | 4      | 22       | DiPE      | T3N0M0| 18.7     | NR      | CHT       |
| Yane              | 2020 | 78  | M   | Tail       | NR       | 2      | 22       | DiPE      | T3N0M0| 26.6     | NR      | Resection |
| Yane              | 2020 | 86  | F   | Body       | NR       | 3      | 22       | DiPE      | T2N0M0| 18.7     | NR      | Resection |
| Yane              | 2020 | 49  | M   | Body       | NR       | 4      | 22       | DiPE      | T2N0M0| 27.8     | NR      | Resection |
| Yane              | 2020 | 79  | F   | Body       | NR       | 3      | 22       | DiPE      | T1N0M0| 36       | NR      | Resection |
| Yane              | 2020 | 78  | F   | Body       | NR       | 4      | 22       | DiPE      | T1N0M0| 34.9     | NR      | Resection |
| Lovecek           | 2022 | 75  | F   | Head       | 25       | 2      | 22       | PPPDE     | T3N0M0| 17       | 20      | PaGE      |
| Lovecek           | 2022 | 71  | F   | Body       | 14       | 2      | 22       | DiPE      | T1N0M0| 23       | 18      | PaGE      |
| Lovecek           | 2022 | 65  | M   | Body       | 30       | 4      | 22       | DiPE      | T3N1M0| 23       | 30      | PaGE      |

M—male; F—female; G—gauge; NR—not reported; Recur—recurrence; DiPE—distal pancreatectomy; CePE—central pancreatectomy; STPE—subtotal pancreatectomy; PPPDE—pylorus preserving pancreatectoduodenectomy; RT—radiotherapy; CHT—chemotherapy; PaGE—partial gastrectomy; WGE—wedge gastrectomy; sTGE—subtotal gastrectomy; TGE—total gastrectomy.
4. Discussion

Seeding following FNA is classified as a long-term and potentially relevant complication. In a retrospective study by Micames et al., peritoneal carcinomatosis in patients with pancreatic cancer is lower, when sampling is performed with the EUS-FNA (2.2%) vs. percutaneous FNA (16.3%) [31]. Needle tract metastases following EUS-FNA present only a very limited number of case reports. However, the fear of seeding is clearly illustrated in the clinical transplantation protocol of Mayo Clinic for the treatment of proximal cholangiocarcinoma [32]. A biopsy of the primary tumor excludes such patients from neoadjuvant therapy and liver transplantation due to a high rate of peritoneal metastasis [32,33]. With the increasing role of neoadjuvant therapy in the treatment of resectable and borderline resectable pancreatic carcinomas, EUS-FNA plays a crucial role in the diagnostic workup in these cases [34]. Despite EUS-FNA sensitivity and specificity reaching 85–89% and 96–99%, the actual guidelines for the management of primary radically operable pancreatic cancer (European Society of Gastrointestinal Endoscopy guidelines, German guidelines—S3) consider EUS-FNA as a non-mandatory method in the management of these cases [1,35,36]. Seeding is considered an overlooked and underestimated problem with clinical impact for the selected group of patients [37]. Current clinical practice is still not following recommendations and guidelines, and most resectable PDAC cases are referred to surgery following EUS-FNA. Kim et al. focused on peritoneal recurrence in a cohort of 411 cases. EUS-FNA was not associated with an increased rate of peritoneal recurrence, decrease in cancer-free survival or overall survival among PDAC patients [2]. However, seeding PDAC metastases (gastric recurrence) were probably missing. The PIPE study concluded that the EUS-FNA of IPMN was not associated with an increased frequency in peritoneal seeding in patients who underwent resection [38]. Despite that, international consensus guidelines (2012) do not recommend cyst fluid analysis and aspiration in mucinous-like pancreatic cystic lesions due to the real risk of peritoneal dissemination [39]. In his review, Minaga et al. (2017) present an increase in the number of case reports with the topic of gastric wall seeding metastases after the EUS-FNA among PDAC patients [15] and the number is still increasing [23–30]. Most of these reports come from Japan [3,8,11–15,19,21–28,30]. Only a number of the reported patients—23 among 30 cases of reported seeding metastases of radically resected PDAC—were subsequently resected with curative intent [3,8,10,13,17,21–30] (Table 3). In the presented group (radical surgery for PDAC 2011–2014 in our institution), the most frequent isolated PDAC metastases treated with curative intent were just gastric metastases, followed by solitary pulmonary oligometastases [40]. According to El Hajj [41], it is very difficult to specify the real clinical risk of seeding of EUS-FNA among PDAC. According to a multicentric analysis of Yane, this clinical situation may exceed to 3.8% [10].

Since the PDAC is a highly lethal malignancy with a very low long-term survival rate, the real rate can only be considered among a specific subgroup of long-term survivors (only around 20% of all PDAC patients who underwent curative-intent surgery reach the 5-year survival) [41,42]. Systemic multiple recurrence (locoregional or/with liver, peritoneal or pulmonary) causes 30% lethality in the first and another 30% during the second postoperative year, respectively. Gastric needle tract metastases could be unidentified due to tumor biology. Based on the current documented cases, we have proposed a general characteristic and criteria of the group of patients, in whom true seeding metastases were evaluated.

4.1. Pathologically Confirmed Primary Diagnosis of the PDAC after Pancreatic Resection

The aggressivity of PDAC is high even in the early stages. In our cohort, the cases were of stage I in one and stage II in two. The reported cases comprised stage I in 7/14 (50%) and stage II in 5/14 (35%) following TNM classification, 7th edition. No lymph node involvement except one and no distant metastases were detected (Table 3). The stage was not reported in six patients. The early stage is considered a favorable prognostic factor in the PDAC-resected patients in our cohort [40]. The first of our cases with N1 status underwent EUS-FNA 22 months prior to surgery. The final stage is supposed to be higher
than the periprocedural one. The delay was caused by adverse post-EUS-FNA events and the initial refusal of surgery.

4.2. Body/Tail Location of the Primary Tumor Is the Most Frequent

Resectable tumors are mostly located in the head of the pancreas. If the EUS-FNA is performed preoperatively, the needle channel is commonly in the duodenum and is usually removed during hemipancreatoduodenectomy. The needle channel is not only resected in cases of non-standard sampling using the needle tract through the gastric antrum or the pylorus. The pylorus-preserving procedure does not remove the needle tract with possible subsequent seeding, as first described in our study. The puncture tract is usually not resected in pancreatic neck and tail tumors, thus enabling the seeding recurrence [3,7,8,10–14,16–19,21,22,24–30]. The pyloric location of gastric metachronous seeding metastasis presented in this study is unique and first published as a result of EUS-FNA. The report of Yang et al. presents a gastric/pyloric metastasis of PDAC of probably hematogenous etiology. In this case, surgical therapy with curative intent was not provided [43].

4.3. Preoperative EUS-FNA

The EUS-FNA for PDAC is considered abundant in HR-CT proven resectability. In S3-leitlinien (German guidelines for resectable pancreatic exocrine tumors and European Society of Gastrointestinal Endoscopy guidelines), the mandatory diagnostic tools include abdominal ultrasound and EUS and the multi-detector high-resolution CT [1,9,35].

Current EUS-FNA indication reveals borderline resectable and locally advanced tumors, in which histopathological diagnosis is needed for the indication/initiation of neoadjuvant therapy. Despite this fact, almost half of resected patients in our study underwent EUS-FNA (N = 59/134).

4.4. 1-Year Survival without Other Recurrences

The evolution of pancreatic cancer and progression lasts over 10 years [44,45]. The datation of potential seeding and growth progression of malignant cells requires EUS-FNA, CT or PET/CT scans and the resected specimen size.

The metastases in our cohort were diagnosed in the second postoperative year, reaching the size of 18–33 mm. The studies focused on EUS-FNA long-term complications, covering only 3 months after the procedure [5]. Seeding tumor progression takes approximately 20 months to grow to a 2 cm tumor (median DFS 22.5 ± 10.6 months; Table 2). There is a good chance to diagnose seeding metastases in the curable stage with longer follow-up and a 3-month interval, as shown in Figure 4 and Table 3. There was a moderate positive correlation between size and time (r = 0.612). The regression coefficient b = 0.72 is significantly non-zero (p = 0.020) and expresses an increase by 0.72 mm in one month.

4.5. Identification of PDAC Tissue in the Resected Specimen (Gastric Wall), with the Exclusion of Direct Invasion and Identical Histopathological Pattern with the Primary Tumor

When the gastric wall lesion is diagnosed in a patient with former PDAC resection, the direct invasion of the previous tumor should be excluded. All of our patients had intact gastric serosa macroscopically during the primary resection. Histopathological evaluation of both gastric mucosa and serosa revealed the tumor localization in the muscle layer. The morphologies of the lesion in the gastric wall and the primary pancreatic tumor were identical.

In our cohort, gastric wall metastasis was diagnosed in 19% of patients meeting the inclusion criteria. Artificial seeding is the most appropriate mechanism of origin of such metastases with surprisingly high incidence.
4.6. Clinical Relevance of Seeding Metastases of PDAC

Seeding metastases following EUS-FNA are less frequent than after percutaneous FNA, but probably more frequent than has been expected. The clinical significance of seeding metastasis targets a small subgroup of relatively good prognosis cases. The direct impact on seeding into mortality has not yet been proven. Subsequent resection of metastasis is necessary for prolonged disease control with possible influence on the overall survival and morbidity.

5. Conclusions

For patients with the PDAC, who are eligible for upfront surgery, the EUS-FNA is not mandatory and the discussion about abandonment of EUS-FNA in such patients seems to be highly relevant. When neoadjuvant therapy is needed, the EUS-FNA is the method of choice for tissue confirmation. If the needle tract has not been removed during radical surgery (primary tumor location in body/tail of the pancreas), the puncture area is the site of the possible seeding/needle tract metastasis development. In our cohort, there was a remarkably high number of seeding metastases. In the case of solitary seeding metastases, radical resection should always be considered. The seeding PDAC metastases are usually diagnosed during the second year after the primary resection with a usual diameter of 15–30 mm. For patients with the EUS-FNA and subsequent radically resected PDAC, without EUS-FNA needle channel being removed, seeding metastases can be a clinically relevant long-term complication with an estimated incidence of 19% in our cohort.

Author Contributions: Conceptualization, M.L., P.S. and O.U.; Data curation, K.U. and B.M.-D.; Formal analysis, M.L., O.U., R.P. and K.U.; Funding acquisition, M.L.; Investigation, M.L., O.U. and M.K.; Methodology, M.L., P.S. and H.S.; Project administration, M.L. and D.K.; Resources, M.L., J.T. and R.P.; Software, M.L. and K.U.; Supervision, D.K. and M.S.; Validation, J.T., M.K., R.P. and H.S.; Visualization, M.S.; Writing—original draft, M.L., B.M.-D. and M.S.; Writing—review and editing, M.L. and M.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Ministry of Health of the Czech Republic, grant NV 19-09-00088 (to M.L.).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of University Hospital Olomouc (protocol code 159/16 and the date of approval 14.11.2016).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained by the patient(s) to publish this paper.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Dumonceau, J.M.; Deprez, P.H.; Jenssen, C.; Iglesias-Garcia, J.; Larghi, A.; Vanbiervliet, G.; Aithal, G.P.; Arcidiacono, P.G.; Bastos, P.; Carrara, S.; et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European society of gastrointestinal endoscopy (ESGE) clinical guideline. Endoscopy 2017, 49, 695–714. [CrossRef] [PubMed]
2. Kim, S.H.; Woo, Y.S.; Lee, K.H.; Lee, J.K.; Lee, K.T.; Park, J.K.; Kang, S.H.; Kim, J.W.; Park, J.K.; Park, S.-W. Preoperative EUS-guided FNA: Effects on peritoneal recurrence and survival in patients with pancreatic cancer. Gastrointest. Endosc. 2018, 88, 926–934. [CrossRef] [PubMed]
3. Tomonari, A.; Katanuma, A.; Matsumori, T.; Yamazaki, H.; Sano, I.; Minami, R.; Sen-Yo, M.; Ikashari, S.; Kin, T.; Yane, K.; et al. Resected tumor seeding in stomach wall due to endoscopic ultrasonography-guided fine needle aspiration of pancreatic adenocarcinoma. World J. Gastroenterol. 2015, 21, 8458–8461. [CrossRef] [PubMed]
4. Hebert-Magee, S.; Bae, S.; Varadarajulu, S.; Ramesh, J.; Frost, A.R.; Eloubeidi, M.A.; Eltoum, I.A. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: A meta-analysis. Cytopathology 2013, 24, 159–171. [CrossRef]
5. Hewitt, M.J.; McPhail, M.J.W.; Possamai, I.; Dhar, A.; Vlavianos, P.; Monahan, K.J. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: A meta-analysis. Gastrointest. Endosc. 2012, 75, 319–331. [CrossRef] [PubMed]

6. Puli, S.R.; Bechtold, M.L.; Buxbaum, J.L.; Eloubeidi, M.A. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass? A meta-analysis and systematic review. Pancreas 2013, 42, 20–26. [CrossRef] [PubMed]

7. Ngamruengphong, S.; Xu, C.; Woodward, T.A.; Raimondo, M.; Stauffer, J.A.; Ashburn, H.J.; Wallace, M.B. Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided finer needle aspiration. Endoscopy 2013, 45, 619–626. [CrossRef]

8. Matsui, T.; Nishikawa, K.; Yukimoto, H.; Katsuta, K.; Nakamura, Y.; Tanaka, S.; Oiwa, M.; Nakahashi, H.; Shomi, Y.; Haruki, Y.; et al. Needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: A report of two cases. World J. Surg. Oncol. 2019, 17, 1–8. [CrossRef]

9. Jessen, C.; Hocke, M.; Fusarolli, P.; Gilja, O.H.; Buscarini, E.; Havre, R.F.; Ignee, A.; Saftoiu, A.; Vilmann, P.; Burmester, E.; et al. EFSUMB guidelines on interventional ultrasound (INVUS). Part IV-EUS-guided interventions: General aspects and EUS-guided sampling (long version). Ultrasschall Der Med.—Eur. J. Ultrasound 2015, 37, E33–E76. [CrossRef]

10. Yane, K.; Kuwatani, M.; Yoshida, M.; Goto, T.; Matsumoto, R.; Ihara, H.; Okuda, T.; Taya, Y.; Ehira, N.; Kudo, T.; et al. Non-negligible rate of needle tract seeding after endoscopic ultrasound-guided fine-needle aspiration biopsy caused dissemination. J. Gastroenterol. Hepatol. 2003, 18, 1323–1324. [CrossRef] [PubMed]

11. Kita, E.; Yamaguchi, T.; Sudo, K. A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomography/CT. Gastrointest. Endosc. 2016, 84, 869–870. [CrossRef] [PubMed]

12. Sakurada, A.; Hayashi, T.; Ono, M.; Ishiwatari, H.; Ogino, J.; Kimura, Y.; Kato, J. A case of curatively resected gastric wall implantation of pancreatic cancer caused by endoscopic ultrasound-guided fine-needle aspiration. Endoscopy 2015, 47, E198–E199. [CrossRef] [PubMed]

13. Hirooka, Y.; Goto, H.; Itoh, A.; Hashimoto, S.; Niwa, K.; Ishikawa, H.; Okada, N.; Itoh, T.; Kawashima, H. Case of inadvertual papillary mucinous tumor in which endosonography-guided needle-needle aspiration biopsy caused dissemination. J. Gastroenterol. Hepatol. 2003, 18, 1323–1324. [CrossRef] [PubMed]

14. Minaga, K.; Takenaka, M.; Katanuma, A.; Kitano, M.; Yamashita, Y.; Kamata, K.; Yamao, K.; Watanabe, T.; Maguchi, H.; Kudo, M. Needle tract seeding: An overlooked rare complication of endoscopic ultrasound-guided fine-needle aspiration. Oncology 2017, 93, 107–112. [CrossRef]

15. Paquin, S.C.; Gariepy, G.; Lepanto, L.; Bourdages, R.; Raymond, G.; Sahai, A.V. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest. Endosc. 2005, 61, 610–611. [CrossRef]

16. Ahmed, K.; Sussmann, J.J.; Wang, J.; Schmulewitz, N. A case of EUS-guided FNA-related pancreatic cancer metastasis to the stomach. Gastrointest. Endosc. 2011, 74, 231–233. [CrossRef]

17. Chong, A.; Venugopal, K.; Segaraejasingam, D.; Lisewski, D. Tumor seeding after EUS-guided FNA of pancreatic tail neoplasms. Gastrointest. Endosc. 2011, 74, 933–935. [CrossRef]

18. Katanuma, A.; Maguchi, H.; Hashigo, S.; Kaneo, M.; Kin, T.; Yane, K.; Kato, R.; Kato, S.; Harada, R.; Osanai, M.; et al. Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. Endoscopy 2012, 44, E160–E161. [CrossRef]

19. Anderson, B.; Singh, J.; Jafri, S.F. Tumor seeding following endoscopic ultrasonography-guided fine-needle aspiration of a celiac lymph node. Dig. Endosc. 2013, 25, 344–345. [CrossRef]

20. Minaga, K.; Kitano, M.; Yamashita, Y. Surgically resected needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration in pancreatic cancer. J. Hepato-Biliary-Pancreat. Sci. 2015, 22, 708–709. [CrossRef] [PubMed]

21. Minaga, K.; Kitano, M.; Enoki, E.; Kashida, H.; Kudo, M. Needle-tract seeding on the proximal gastric wall after EUS-guided fine-needle aspiration of a pancreatic mass. Am. J. Gastroenterol. 2016, 111, 1515. [CrossRef] [PubMed]

22. Iida, T.; Adachi, T.; Ohe, Y.; Nakagaki, S.; Yabana, T.; Kondo, Y.; Nakase, K. Re-recurrence after distal gastrectomy for recurrence caused by needle tract seeding during endoscopic ultrasound-guided fine-needle aspiration of a pancreatic adenocarcinoma. Endoscopy 2016, 48, E304–E305. [CrossRef]

23. Yamauchi, J.; Kobayashi, S.; Miyazaki, K.; Aji, T.; Tsuchihara, K.; Ishiyama, S. A case of curative resection of needle tract seeding after EUS-guided fine needle aspiration for pancreatic body cancer. J. Japan Surg. Assoc. 2016, 77, 2994–2999. [CrossRef]

24. Matsumoto, K.; Kato, H.; Tanaka, N.; Oka, H. Preoperative detection of tumor seeding after endoscopic ultrasonography-guided fine needle aspiration for pancreatic cancer. Intern. Med. 2018, 57, 1797–1798. [CrossRef] [PubMed]

25. Sakamoto, U.; Fukuban, N.; Ishihara, S.; Sumi, S.; Okuda, M.; Sonoyama, H.; Oshima, N.; Moriyama, I.; Kawashima, K.; Kinoshita, Y. Postoperative recurrence from tract seeding after use of EUS-FNA for preoperative diagnosis of cancer in pancreatic tail. Clin. J. Gastroenterol. 2018, 11, 200–205. [CrossRef]

26. Kawabata, H.; Miyazawa, Y.; Sato, H.; Hayashi, A.; Iwama, T.; Fujibayashi, S.; Goto, T.; Sasajima, J.; Takauji, S.; et al. Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB. Endosc. Int. Open 2019, 07, E1768–E1772. [CrossRef]
